Kody Technolab Executes Global Medical Robot Supply and Intellectual Property Agreement with Falcon Tech Robotics and Sccore AI Tech Diagnostic

HIGHLIGHT:

What Happened ?

Key Details

Strategic Healthcare Robotics Commercialization Agreement:

• Agreement executed between Kody Technolab Limited, Falcon Tech Robotics LLC and Sccore AI Tech Diagnostic Limited.
• Objective is the global manufacture, supply, distribution, deployment and commercialization of healthcare robotic screening solutions.
• Agreement validity is three years from the effective date unless terminated earlier under contractual provisions.
• Kody will manufacture healthcare robotic products covered under the agreement.
• Falcon Tech Robotics will undertake distribution responsibilities.
• Sccore AI Tech Diagnostic will manage deployment and commercialization globally.
• Covered product portfolio includes Medigo Static, Medigo Kids, Medigo Women and Medigo Mobile.
• Agreement contains provisions related to exclusivity, software support, confidentiality, warranties, intellectual property protection, indemnities and dispute resolution.
• Disputes, if any, will be resolved through arbitration under the Dubai International Arbitration Centre (DIAC), UAE.
• The arrangement is intended to facilitate worldwide deployment and commercial scaling of Kody’s healthcare robotics platform.

Note:

• Falcon Tech Robotics LLC is a joint venture entity of Kody Technolab Limited. Accordingly, the transaction qualifies as a related party transaction. The company has disclosed that the agreement has been executed on an arm’s length basis and in the ordinary course of business.

Risk Analysis

Summary:

• While the agreement opens new international commercialization opportunities, execution success will depend on product deployment, customer adoption, distributor performance and achievement of minimum purchase commitments under the contract.

Key Risks:

• The agreement includes minimum purchase commitment requirements from Sccore AI Tech Diagnostic.
• Failure to meet purchase obligations may trigger cessation of exclusive manufacturing and supply rights under the agreement.
• Commercial success depends on large-scale adoption of healthcare robotic screening solutions.
• International deployment may involve regulatory, operational and market-entry challenges.
• Related-party nature of the transaction may attract additional governance scrutiny despite arm’s length certification.
• Revenue contribution and commercialization timelines have not been disclosed.

Worst Case:

• If minimum purchase commitments are not achieved or commercialization efforts fail to gain traction, the strategic partnership may not generate the anticipated international business opportunities and exclusivity provisions could cease under the agreement.

Risk Level: Medium

Company Commentary

• The agreement establishes a strategic commercial framework for worldwide deployment of Kody Technolab’s proprietary healthcare screening robots and software solutions.
• The collaboration is expected to strengthen the company’s position within the healthcare robotics sector.
• Management believes the arrangement will expand international market presence and support long-term business opportunities through large-scale deployment of medical robotic solutions.
• The agreement covers manufacturing, supply, distribution, deployment and commercialization responsibilities among the participating parties.